pemetrexed,cisplatin,gemcitabine,pembrolizumab
merck
['biomarker', 'nsclc', 'sclc']
 provided an excellent discussion about the timing of immunotherapy in locally-advanced nsclc. highlighted the need for biomarkers and biomarker testing. must weigh benefits and drawbacks for continuing trx for 1 year post surgery #asco23 
LUNGevity, the nation’s leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer.